Margin Pressure from Drug Price Revisions and Generic-Drug Promotion
First written in FY2016. 17 of 26 entries say "Materialised", first in FY2017-Q1. Latest entry: FY2026-H1.
Seikagaku moved to the "Worse" side of this theme in 2016, 4 years before the typical company in this theme (2020).
The whole theme swung hardest in 2018: 20 of 65 companies on the "Worse" side.
47 other companies' latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「The company's sales increased 8.0% year on year. Although sales declined because of lower unit prices for OPEGAN products and other factors, the increase resulting from the timing of Alts shipments more than offset the decline.」
While sales of OPEGAN products continued to decline because of lower unit prices, the increase resulting from the timing of Alts shipments lifted total domestic pharmaceutical sales. - FY2025MaterialisedAnnual report
「For Alts, switching from competing products progressed and the number of units delivered to medical institutions increased from the previous fiscal year. In addition, maintenance of equipment in preparation for expanding production capacity at the company's plant was completed, and shipment volumes increased from the previous fiscal year. However, sales declined from the previous fiscal year because of the impact of lower unit prices.」
Although the number of units delivered and shipment volumes of domestic Alts increased, sales declined because of lower unit prices, and earnings pressure from price controls was reflected in the results. - FY2024MitigatedAnnual report
「Switching from competing products progressed for Alts, a treatment for improving joint function, and the number of units delivered to medical institutions increased. As a result, the company's sales increased despite the impact of cuts to official drug prices.」
Although the impact of cuts to official drug prices remained, the disclosure indicated that the company's sales of Alts increased as switching from competing products progressed and the number of units delivered rose, offsetting the impact. - FY2024-Q3RestatedAnnual report
「Alz, a joint-function improvement agent, saw the number of units delivered to medical institutions increase as measures to promote switching from competing products proved successful. Our sales increased on higher shipment volumes, despite the impact of drug-price reductions.」
Although the earnings pressure from cuts to official drug prices remained, the company's sales of Alts increased as shipment volumes rose, and the company continued to offset the impact. - FY2024-Q1Higher volumes offset the impact of official drug price cutsAnnual report
「Alz, a joint-function improvement agent, saw the number of units delivered to medical institutions increase as measures to promote switching from competing products proved successful. Our sales increased on higher shipment volumes, despite the impact of drug-price reductions.」
Although the impact of cuts to official drug prices remained, the company's sales of Alts increased as the number of units delivered and shipment volumes rose following switches from competing products. - FY2023-Q3MaterialisedAnnual report
「Measures to switch from competing products proved effective for Alts, a treatment for improving joint function, and the number of units delivered to medical institutions increased. The company's sales declined because of cuts to official drug prices, although shipment volumes increased as a result of shipment timing.」
Although the number of Alts units delivered increased as a result of switching from competing products, the company's sales declined because of cuts to official drug prices, and the continuing earnings pressure was reflected in the results. - FY2023-Q2MaterialisedAnnual report
「Alz, a joint-function improvement agent, saw the number of units delivered to medical institutions increase as the market recovered from the impact of COVID-19 and measures to promote switching from competing products proved successful. Our sales declined because of drug-price reductions, although shipments increased due to shipment-timing effects.」
The earnings pressure from cuts to official drug prices continued to be reflected in the results as a factor behind the decline in the company's sales despite the increase in the number of Alts units delivered to medical institutions. The disclosure also states that sales of MucoUp declined because of the impact of revisions to reimbursement prices. - FY2023-Q1MaterialisedAnnual report
「• Domestic pharmaceuticals (¥2,965 million, down 22.9% year on year) Alts, a treatment for improving joint function, saw an increase in the number of units delivered to medical institutions as the market continued to recover from the effects of COVID-19 and measures to switch from competing products proved effective. The company's sales declined because of the impact of cuts to official drug prices, although shipment volumes increased as a result of shipment timing adjustments.」
Domestic pharmaceutical sales declined 22.9% year on year, and the decline in the company's Alts sales due to cuts to official drug prices was reflected in the results. - FY2022-Q3WorsenedAnnual report
「Although market conditions for Alts in China became increasingly difficult because of government price-control measures and other factors, local unit sales increased as a result of proactive sales-promotion activities and the expansion of the sales organization.」
The disclosure states that market conditions for Alts in China were becoming increasingly difficult because of government price-control measures and other factors. Meanwhile, local unit sales increased as a result of sales-promotion activities and the expansion of the sales organization. - FY2022-Q2MaterialisedAnnual report
「For OPEGAN ophthalmic surgical aids, the number of units delivered to medical institutions increased as the market recovered from the contraction caused by the decline in cataract surgeries associated with the spread of COVID-19 in the same period of the previous year. The company's sales declined because shipments in the same period of the previous year were high and because of the impact of cuts to official drug prices.」
The impact of cuts to official drug prices continued to be reflected in the results as a decline in the company's sales of OPEGAN products. By contrast, the number of units delivered increased as a reaction to the decline in the same period of the previous year. - FY2022-Q1MaterialisedAnnual report
「The company's sales declined because of the impact of cuts to official drug prices and the high level of shipments in the same period of the previous year.」
The earnings pressure from cuts to official drug prices continued to be reflected in the results as a factor behind the decline in the company's sales of Alts. - FY2021MaterialisedAnnual report
「Domestic pharmaceuticals (¥12,019 million, down 12.1% year on year)」
Domestic pharmaceutical sales declined 12.1% year on year against a backdrop of cuts to official drug prices and a decline in outpatient visits due to COVID-19. - FY2021-Q3MaterialisedAnnual report
「Domestic pharmaceuticals (¥9,617 million, down 16.2% year on year)」
Domestic pharmaceutical sales declined 16.2% year on year, and the impact of cuts to official drug prices continued to be reflected in the results. - FY2021-Q2MaterialisedAnnual report
「• Domestic pharmaceuticals (¥6,278 million, down 13.5% year on year)」
Domestic pharmaceutical sales declined 13.5% year on year, and the impact of cuts to official drug prices continued to be reflected in the results. The company's sales of Alts also declined because of the price cuts. - FY2020MaterialisedAnnual report
「Full-year net sales were ¥28,642 million, up 0.9% year on year, as the increase in overseas pharmaceutical sales offset the decline in domestic pharmaceutical sales caused by cuts to official drug prices.」
The decline in domestic pharmaceutical sales caused by cuts to official drug prices was reflected in the full-year results, while higher overseas pharmaceutical sales offset the decline at the overall level. - FY2019WorsenedAnnual report
「The company's sales declined substantially as a result of the cuts to official drug prices implemented in April 2018.」
The fundamental reform of the official drug pricing system and substantial price cuts were reflected in the full-year results as a significant decline in domestic Alts sales and a 12.2% year-on-year decline in domestic pharmaceutical sales. - FY2019-Q3MaterialisedAnnual report
「• Domestic pharmaceuticals (¥10,938 million, down 15.1% year on year) Alts, a treatment for improving joint function, saw a slight increase in the number of units delivered to medical institutions as the sales partner expanded its sales efforts in connection with the launch of an improved formulation addressing user needs, even as the market as a whole contracted on a unit basis. However, the company's sales declined substantially as a result of cuts to official drug prices.」
The cuts to official drug prices implemented from April 2018 continued to be reflected in the results, with domestic pharmaceutical sales down 15.1% year on year and the company's sales of Alts down substantially. - FY2019-Q2MaterialisedAnnual report
「Domestic pharmaceuticals (¥6,974 million, down 17.5% year on year)」
Sales of domestic pharmaceuticals declined 17.5% year on year as a result of cuts to official drug prices implemented from April 2018. The earnings pressure from the price revision was again reflected in the results for the quarter. - FY2019-Q1MaterialisedAnnual report
「Domestic pharmaceuticals (¥3,501 million, down 15.0% year on year)」
Sales of domestic pharmaceuticals declined 15.0% year on year due to cuts to official drug prices implemented from April 2018 and other factors. The earnings pressure from the price revision was reflected in the results for the quarter. - FY2018-Q3RestatedAnnual report
「Although the effects of government price-control measures and other factors on Alts in China were beginning to subside, local sales declined slightly.」
While the disclosure continues to state that the effects of price-control measures on Alts in China were beginning to subside, local sales declined slightly. - FY2018-Q1MitigatedAnnual report
「Local sales of Alts in China increased as the effects of government price-control measures and other factors began to subside, but the company's sales declined because of local inventory adjustments.」
The disclosure states that the impact of government price-control measures on sales of Alts in China was beginning to subside. However, the company's sales declined because of local inventory adjustments. - FY2017MaterialisedAnnual report
「Net sales for the fiscal year were ¥29,589 million, down 4.4% from the previous fiscal year. Although unit sales of domestic pharmaceuticals, U.S. Gel-One and the overseas LAL business increased, sales were affected by the stronger yen and cuts to official drug prices in Japan.」
Cuts to official drug prices in Japan, together with the stronger yen, actually emerged as a factor behind the decline in full-year sales. - FY2017-Q3MaterialisedAnnual report
「Consolidated net sales for the third quarter cumulative period were ¥22,128 million, down 5.6% year on year. Although unit sales of U.S. Gel-One and the overseas LAL business increased, sales were affected by the stronger yen and cuts to official drug prices in Japan.」
Cuts to official drug prices in Japan, together with the stronger yen, actually contributed to the decline in cumulative sales through the third quarter. The disclosure also states that local sales of Alts in China declined as a result of government price-control measures. - FY2017-Q2MaterialisedAnnual report
「Consolidated net sales for the second quarter cumulative period were ¥15,085 million, down 5.4% year on year. Although unit sales of U.S. Gel-One and domestic pharmaceuticals increased, sales were affected by the stronger yen and cuts to official drug prices in Japan.」
Cuts to official drug prices in Japan, together with the stronger yen, actually contributed to the decline in cumulative sales for the quarter. - FY2017-Q1MaterialisedAnnual report
「Consolidated net sales for the first quarter cumulative period were ¥8,275 million, up 6.6% year on year. Although sales were affected by the stronger yen and cuts to official drug prices in Japan, the increase was supported by higher unit sales of overseas pharmaceuticals and advance shipments of domestic pharmaceuticals, among other factors.」
The disclosure states that cuts to official drug prices in Japan actually affected sales in the quarter. - FY2016First statedAnnual report
「To reduce medical costs, the use of lower-priced generic drugs is being promoted, and additional cuts to the official prices of long-listed products are being implemented.」
The disclosure states that Alts was affected domestically by the promotion of generic drug use, while similar price-control measures overseas are also identified as a risk.